Source: Eur Respir J 2007; 30: 951-956
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Garcia-Vidal C., Calbo E., Pascual V., Ferrer C., Quintana S., Garau J.. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30: 951-956

Member's Comments

No comment yet.

Related content which might interest you: Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Systemic cytokine response in patients with community-acquired pneumonia Source: Eur Respir J 2011; 37: 1431-1438 Year: 2011 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003 Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Effects of glucocorticoids in ventilated piglets with severe pneumonia Source: Eur Respir J 2008; 32: 1037-1046 Year: 2008 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Systemic cytokine levels in community-acquired pneumonia and their association with disease severity Source: Eur Respir J 2002; 20: 990-995 Year: 2002 Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010 Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007 CD4 as a predictor of systemic inflammatory response and death at severe community-acquired pneumonia Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Respiratory pathogens, immunodeficiency or systemic response – What comes first in the etiology of severe community-acquired pneumonia (sCAP) Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013